Swiss National Bank Purchases 5,200 Shares of Palvella Therapeutics, Inc. $PVLA

Swiss National Bank increased its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 36.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,400 shares of the company’s stock after buying an additional 5,200 shares during the period. Swiss National Bank’s holdings in Palvella Therapeutics were worth $2,418,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in PVLA. Group One Trading LLC lifted its stake in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the period. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics during the 3rd quarter valued at about $36,000. JPMorgan Chase & Co. increased its position in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at about $85,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at about $104,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $150.19 on Friday. The company’s 50-day simple moving average is $129.69 and its 200-day simple moving average is $118.14. Palvella Therapeutics, Inc. has a fifty-two week low of $34.57 and a fifty-two week high of $161.38. The stock has a market capitalization of $2.15 billion, a P/E ratio of -36.02 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, research analysts forecast that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on PVLA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Stephens restated an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Chardan Capital reaffirmed a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.